Pacific Bio (NASDAQ: PACB) reported Q4 EPS of ($0.30), $0.02 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $36 million versus the consensus estimate of $36.12 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.